Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
The US Food and Drug Administration approved Merck's LIPFENDRA (enlicitide) 20 mg tablets Thursday July 16, 2026 as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA is a novel macrocyclic peptide and becomes the first FDA-approved oral PCSK9 inhibitor. In the registrational Phase 3 CORALreef Lipids trial, enlicitide achieved a 56% placebo-adjusted LDL-C reduction; in CORALreef HeFH the reduction was 59%. Every other FDA-approved PCSK9 inhibitor (Amgen's Repatha/evolocumab, Regeneron/Sanofi's Praluent/alirocumab) is delivered by subcutaneous injection every two to four weeks; enlicitide is the first approved as a once-daily oral tablet. Merck priced LIPFENDRA at $315 per month list price, roughly one-third the approximately $700-900/month list prices of the injectable PCSK9 antibodies. The approval extends the macrocyclic peptide platform's clinical validation and opens a new oral chapter for a drug class that had been injectable-only since the first FDA approvals in 2015.
The House Select Committee on the Chinese Communist Party's July 17, 2026 response deadline arrives tomorrow for five drugmakers on records of clinical trials conducted at Xinjiang-region hospitals and Chinese military medical centers: Merck, AbbVie, Eli Lilly, Pfizer, and Bristol-Myers Squibb. Chair Rep. John Moolenaar (R-Michigan) sent letters on June 29 requesting due diligence, data protection processes, and standards at Chinese trial sites. Updated trial counts documented in the letters: Merck sponsored or collaborated on 224 clinical studies in China since 2005, including at least 31 trials involving Xinjiang-region hospitals and at least 40 trials involving Chinese military medical centers. Eli Lilly appears to have sponsored or collaborated on more than 220 clinical studies in China since 2003, with at least 11 Xinjiang-region trials and at least 16 military-medical-center trials between 2016 and 2024. Pfizer had at least 6 Xinjiang-region trials and 43 military-hospital trials. AbbVie had 17 Xinjiang and 16 military. Bristol-Myers Squibb's specific counts were not detailed in the summary but the company received the same request. Merck stated that patient safety and ethical integrity are foundational to its clinical research; Eli Lilly said it is reviewing the letter closely.
SOTIO Biotech (a portfolio company of PPF Group) announced Tuesday July 14, 2026 that the US Food and Drug Administration (FDA) granted Fast Track Designation to SOT109, its investigational potentially best-in-class antibody-drug conjugate (ADC), for the treatment of patients with advanced unresectable or metastatic colorectal cancer (CRC) who have exhausted standard treatment options. SOT109 targets cadherin 17 (CDH17), a cell-surface antigen expressed in more than 90% of CRC cases and broadly across gastrointestinal malignancies, supporting the case for broad clinical utility and a favorable therapeutic index. SOTIO expects to initiate a Phase 1/2 trial of SOT109 in patients with advanced unresectable or metastatic CRC in Q3 2026. Fast Track Designation allows more frequent FDA-sponsor interactions and eligibility for accelerated approval and priority review if criteria are met. The SOT109 program extends the broader payload-and-linker-chemistry investment thesis anchored by Novartis's July 6 Myricx Bio $1.5 billion NMTi acquisition and Lonza's July 2 Nona Biosciences TfR1 BBB-delivery deal.
STAT News' Pharmalot newsletter reported Wednesday-Thursday July 8-9, 2026 that the White House is reviewing three finalists to lead the FDA following the departure of the prior commissioner earlier in 2026: Heidi Overton, a policy adviser in the White House itself; Jeffrey Vacirca, an oncologist and health-system executive; and Stephen Ferrara, a health official at the Department of Defense. Axios first surfaced the shortlist on June 26; the July 8-9 STAT reporting confirmed the trio is under active White House review with a decision expected in the coming weeks. The peptide policy trajectory tracks through whichever nominee advances. FDA career-staff briefing documents released June 29-30 concluded all seven PCAC peptides have insufficient evidence for 503A eligibility, while HHS Secretary RFK Jr.'s public push points the other direction; the incoming commissioner will inherit an agency-vs-secretary tension around peptide compounding as the July 23-24 PCAC vote lands. The nominee will also inherit the pending Novo Nordisk-Vivani semaglutide-implant evaluation agreement, the Sandoz generic-tirzepatide ANDA acceptance from June 29, and the ongoing 503B GLP-1 exclusion rulemaking.
The House Select Committee on the Chinese Communist Party (chaired by Rep. John Moolenaar, R-Michigan) faces its July 17 response deadline one week from tomorrow for five drugmakers under national-security investigation over clinical trials conducted at Chinese sites: Eli Lilly, Merck, AbbVie, Pfizer, and Bristol-Myers Squibb. The letters, first reported by Reuters, were dated June 29 and asked companies to provide details of due diligence, data protection processes, and other standards at their trial sites in China, with particular attention to the Xinjiang region and military hospitals. Eli Lilly disclosed sponsoring at least 11 trials at Xinjiang-region hospitals plus at least 16 trials at Chinese military medical centers and hospitals, across type 2 diabetes, heart disease, obesity, Alzheimer's disease, axial spondyloarthritis, breast cancer, lupus, alopecia, Crohn's disease, and additional indications. The committee said it has no evidence of company wrongdoing but cites potential ethical and national-security risks. The letters run parallel to the BIOSECURE Act framework, the June 30 STAT Pharmalittle preview of the probe, and industry warnings from Fierce Biotech that the scrutiny risks 'huge distraction and expense' for US biopharma.
The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its member-review cutoff Thursday July 9, 2026 at 11:59 PM ET. Submissions filed by this deadline go into the reading packet PCAC members review ahead of the July 23-24 meeting. Written comments filed after today remain on the public record and inform final agency deliberations but do not reach panelists before their initial preparation. The absolute hard deadline for all written comment submissions is 11:59 PM ET on Wednesday July 22, 2026, one day before the meeting opens at White Oak. The docket has attracted comments from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices), academic scientists (UC Davis's Paul Knoepfler), and individual physicians and patients on both sides. The FDA career-staff briefing documents released June 29-30 concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity, heavy-metal and microbial contamination in compounded samples, mislabeled contents, and thin 503A historical use. The July 9 threshold locks in the reading pile that panelists carry into the July 23 vote.
Endpoints News published a mid-year FDA review Wednesday reporting that the FDA cleared 23 novel drugs through June 30, 2026, the best first half of a year for novel approvals since 2023. The pace held up despite the Trump administration's April 2025 FDA staff cuts that industry observers had feared would slow the approval machine. Total regulatory verdicts in H1 2026 ran 79 (slight decrease from 85 in H1 2025), but novel approvals ticked up substantially from 19 in H1 2025 to 26 by the Endpoints tally (approaches vary slightly by definition; the FDA's Novel Drug Approvals for 2026 tracker shows 23 through the June 30 cutoff). Approvals during the period spanned oncology, infectious disease, nephrology, dermatology, ophthalmology, and metabolic disease. The peptide-relevant approvals within this pace include Yuviwel (navepegritide, Ascendis Pharma's once-weekly C-type natriuretic peptide prodrug for pediatric achondroplasia; accelerated approval February 27), Foundayo (orforglipron, Eli Lilly's oral small-molecule GLP-1 for chronic weight management; April 1), Tryngolza (olezarsen, Ionis's ASO for severe hypertriglyceridemia; June 24), and Trutakna (atacicept, Vera Therapeutics' BAFF/APRIL fusion protein for IgA nephropathy; July 7). The staff-cut concern has partially receded, though longer-term impacts on Center for Drug Evaluation and Research (CDER) throughput remain a Q3-Q4 2026 story to watch.
The FDA granted accelerated approval Tuesday July 7, 2026 to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, in combination with standard of care. Vera Therapeutics developed the drug as a recombinant fusion protein that combines the extracellular domain of the transmembrane activator and CAML interactor (TACI) receptor with the Fc portion of human IgG1, binding both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) to reduce autoantibody-driven kidney damage. The registrational Phase 3 ORIGIN trial data supporting approval: at 36 weeks, Trutakna plus standard of care produced a 45.7% reduction in urine protein-to-creatinine ratio versus a 6.8% reduction for standard of care alone. IgA nephropathy affects approximately 130,000 to 150,000 Americans and is the most common primary glomerular disease worldwide; approximately 40% of patients progress to end-stage renal disease within 20 years without adequate treatment. Trutakna is a fusion protein rather than a peptide but sits in adjacent therapeutic territory relevant to the site's peptide-and-biologic coverage. Vera Therapeutics (NASDAQ: VERA) is expected to launch the product in Q3 2026. Continued approval may be contingent on verification of clinical benefit in confirmatory Phase 3 studies.
The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its first procedural cutoff Thursday July 9, 2026 at 11:59 PM ET. Comments submitted by this deadline will be formally provided to PCAC members ahead of the July 23-24 meeting. Written submissions after July 9 remain on the record but reach members after their initial review preparation. The docket's absolute hard deadline for all written comment submissions is July 22, 2026 at 11:59 PM ET (one day before the meeting opens). Compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer advocacy voices (Public Citizen), academic researchers (UC Davis's Paul Knoepfler), and individual physicians have filed comments across both the pro-approval and pro-restriction sides of the panel decision. The FDA career-staff briefing documents (released June 29-30) concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity concerns, heavy-metal and microbial contamination in compounded product samples, mislabeled contents, and thin 503A historical use. The July 9 threshold is the operational moment at which panelists get their reading pile; the record they use to deliberate the July 23-24 vote is set today.
On July 5, Ascletis submitted two INDs to the FDA: ASC36, a peptide amylin receptor agonist dosed once monthly to once quarterly by injection, and ASC36_35, a co-formulation pairing ASC36 with the GLP-1R/GIPR agonist peptide ASC35. In diet-induced obese rat studies, ASC36 monotherapy showed roughly 91% and 32% greater relative body-weight reduction than petrelintide and eloralintide, and the ASC36_35 combination showed about 51% greater reduction than co-administered eloralintide plus tirzepatide. The filings push amylin biology further into the obesity race.
Writing in STAT on July 6, Jerome Adams, the 20th US Surgeon General, argues the FDA should reject both an outright ban and unrestricted access ahead of the July 23-24 Pharmacy Compounding Advisory Committee vote. He proposes allowing select peptides through licensed 503A pharmacies under strict quality controls, requiring clinician evaluation and informed-consent documentation, and mandating real-world outcome tracking to build the safety and efficacy data that gray-market 'research use only' products never generate. The piece notes acting FDA commissioner Kyle Diamantas and a follow-up review expected before February 2027.
On June 26, Lantheus disclosed a complete response letter for LNTH-2501, its gallium-68 edotreotide PET diagnostic kit for locating somatostatin-receptor-positive neuroendocrine tumors in adults and children. The FDA cited unresolved inspection conditions at the third-party facility that manufactures the drug product and could not approve by the June 29 PDUFA date. The agency raised no concerns about the clinical data, safety, or efficacy. CEO Mary Anne Heino said the feedback 'relates solely to our third-party manufacturer, and not to the clinical performance of the product.'
Sandoz Group announced Monday June 29, 2026 that the FDA accepted two Abbreviated New Drug Applications (ANDAs) from the company for generic versions of Eli Lilly's tirzepatide autoinjectors, covering the type-2-diabetes-labeled Mounjaro and the obesity-labeled Zepbound. The ANDAs cover all approved indications of Mounjaro and Zepbound. If approvals land, Sandoz would launch 'one of the first generic tirzepatide products' in the US, adding real supply-side competition to Lilly's branded product and creating pricing pressure that could reshape the Medicare GLP-1 Bridge economics. The company developed the generic tirzepatide in-house, combining Sandoz's small-molecule and device-development experience with its biosimilar expertise. The ANDA acceptance does not include a projected FDA action date; typical generic-tirzepatide review timelines run 12 to 24 months, putting a potential Sandoz launch window in 2027-2028. The competitive-pressure question is whether generic tirzepatide substitution would apply at the pharmacy counter under the Bridge (the program covers Zepbound KwikPen brand-specifically) or only in the broader Part D market post-Bridge.
Paul Knoepfler, professor at the University of California, Davis, School of Medicine and a widely followed stem-cell and regenerative-medicine researcher, told The Washington Post this week that the FDA's July 23-24 Pharmacy Compounding Advisory Committee panel has been reshaped in a way that raises concerns about the vote. His direct quote: 'It seems RFK Jr. stacked the committee.' Knoepfler's academic-scientist voice joins the growing critic chorus that has developed over the past two weeks around the PCAC review: FDA career-staff briefing documents (June 29-30) concluding none of the seven peptides has sufficient evidence for 503A bulks list eligibility; STAT News' Lizzy Lawrence scoop on the eight new panelists with peptide industry ties; Public Citizen's July 'Outrage of the Month' advocacy position; BioCentury's industry-analyst piece; and mainstream coverage across NBC News, NPR, CNN, PBS NewsHour, and the Associated Press wire syndicated through hundreds of regional outlets. The Knoepfler quote is the clearest single-line summary of the concerns and will likely circulate as the durable framing of the panel-composition question through the July 23 vote.
US News, syndicating an Associated Press wire story, published a piece Wednesday July 1, 2026 titled 'FDA Scientists Warn Against Expanded Peptide Access As Kennedy Reshapes Advisory Panel,' continuing the mainstream-media coverage of the FDA career-staff briefing documents that landed Monday-Tuesday June 29-30. The AP framing tied together two threads that STAT News, NBC News, NPR, Washington Post, PBS NewsHour, and CNN had covered separately: the substantive staff position that none of the seven peptides (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence for 503A bulks list eligibility; and the parallel panel-composition story flagging that at least seven of the eight new PCAC panelists named Monday have ties to peptide-related businesses and clinics. The AP wire distribution amplifies the story to hundreds of regional papers and broadcast outlets, extending public awareness well beyond the health-policy audience that read the original STAT scoop. Public Citizen's July 'Outrage of the Month' column, BioCentury's industry-analyst piece, and Personal Care Insights coverage each add to the growing critic chorus three weeks before the July 23-24 PCAC vote.
PolitiFact published a primer piece Wednesday July 1, 2026 titled 'A primer on retatrutide and compassionate use,' laying out the underlying facts of the STAT News June 23 disclosure for readers coming to the story after two weeks of political-controversy coverage. The primer format explained: what compassionate use is (the FDA's expanded-access single-patient IND pathway, 21 CFR 312 Subpart I, ~1,800 requests per year at 99%+ approval); what retatrutide is (Eli Lilly's investigational GLP-1/GIP/glucagon triple agonist, still in Phase 3, TRIUMPH-1 topline 28.3% mean weight loss at 12 mg over 80 weeks); the STAT News reporting timeline (June 23 initial scoop by Lizzy Lawrence, June 25 Senator Hassan letter, June 26 Rep. Ted Lieu press conference, June 29 White House pushback); and what remains unconfirmed (the patient's identity, Lilly's specific rationale for granting the compassionate-use request, whether the White House denial framing constitutes a categorical denial or a non-denial). PolitiFact did not confirm the patient's identity and did not issue a rating on any specific claim; the piece functions as fact-based reference material for the broader public conversation. The primer format is likely to circulate as the reference PolitiFact link for future stories on the case.
The Centers for Medicare and Medicaid Services' Medicare GLP-1 Bridge demonstration program launched Wednesday July 1, 2026, opening prior-authorization submissions through Humana as central processor and activating the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR). The program provides eligible Medicare Part D beneficiaries with $50/month access to four FDA-approved obesity drugs: Foundayo (orforglipron oral tablets, Eli Lilly), Wegovy injection (semaglutide, Novo Nordisk), Wegovy tablets (oral semaglutide in 1.5, 4, 9, and 25 mg strengths), and Zepbound KwikPen (tirzepatide single-dose autoinjector, Eli Lilly). CMS targets 72-hour prior-authorization turnaround. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Part D. It represents the first time Medicare has helped pay for drugs prescribed solely for obesity, breaking the 2003 Medicare Modernization Act exclusion that had barred obesity-only prescriptions from Part D coverage.
Becker's Payer Issues published a launch-day analysis titled '4 questions linger as CMS launches the Medicare GLP-1 Bridge' identifying operational uncertainties in the program even as the first prescriptions begin flowing. The four questions: (1) CMS could not confirm cost or enrollment projections on the launch call, leaving analyst modeling of program cost dependent on informal expectations from CMS Medicare Director Chris Klomp; (2) how quickly enrollment will build past Klomp's 'single-digit millions' framing given the manual prior-authorization workflow; (3) the absence of a formal appeals process within the Bridge itself (providers can resubmit eligibility forms repeatedly but there is no defined appeals track for denied prior authorizations); (4) whether manufacturer-negotiated pricing arrangements will hold at the $245 net price if utilization runs above expectations. The Bridge bypasses Part D sponsors entirely, in contrast to the voluntary Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model launching January 2027 in Part D, which required sponsors to sign on. The Bridge's central-processor architecture through Humana handles all payment and prior-authorization traffic outside the standard Part D benefit structure.